Holen Sie sich die Stockscreener-App
334.80
1.03%
-3.485
Handel nachbörslich:
345.00
10.20
+3.05%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt MDGL?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$338.29
Offen:
$339.52
24-Stunden-Volumen:
255.77K
Relative Volume:
0.56
Marktkapitalisierung:
$7.30B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-518.67M
KGV:
-13.33
EPS:
-25.12
Netto-Cashflow:
$-438.32M
1W Leistung:
+2.03%
1M Leistung:
+8.50%
6M Leistung:
+17.61%
1J Leistung:
+54.49%
1-Tages-Spanne:
$334.02
$347.20
1-Wochen-Bereich:
$300.00
$347.20
52-Wochen-Spanne:
$168.25
$368.29
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
Firmenname
Madrigal Pharmaceuticals Inc
Sektor
Branche
Telefon
404-380-9263
Adresse
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Vergleichen Sie MDGL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
334.80 | 7.30B | 0 | -518.67M | -438.32M | -25.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-06-28 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2024-06-11 | Eingeleitet | Wolfe Research | Outperform |
| 2024-04-22 | Eingeleitet | BofA Securities | Underperform |
| 2024-03-15 | Hochstufung | B. Riley Securities | Sell → Neutral |
| 2024-03-06 | Eingeleitet | Citigroup | Buy |
| 2024-02-26 | Herabstufung | B. Riley Securities | Neutral → Sell |
| 2022-12-20 | Bestätigt | Oppenheimer | Outperform |
| 2022-12-19 | Bestätigt | H.C. Wainwright | Buy |
| 2022-12-19 | Bestätigt | Piper Sandler | Overweight |
| 2022-12-19 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2022-07-08 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-08-06 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-05-20 | Fortgesetzt | Goldman | Buy |
| 2020-11-24 | Fortgesetzt | Evercore ISI | Outperform |
| 2020-11-06 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-31 | Eingeleitet | Piper Sandler | Overweight |
| 2020-06-05 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2020-05-05 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-01-30 | Eingeleitet | Canaccord Genuity | Buy |
| 2020-01-09 | Hochstufung | UBS | Neutral → Buy |
| 2019-11-07 | Bestätigt | H.C. Wainwright | Buy |
| 2019-06-25 | Eingeleitet | Stifel | Hold |
| 2019-06-10 | Hochstufung | B. Riley FBR | Neutral → Buy |
| 2019-02-28 | Bestätigt | H.C. Wainwright | Buy |
| 2019-02-22 | Eingeleitet | SVB Leerink | Outperform |
| 2019-01-23 | Eingeleitet | UBS | Neutral |
| 2018-12-14 | Eingeleitet | Wolfe Research | Outperform |
| 2018-12-12 | Eingeleitet | B. Riley FBR | Neutral |
| 2018-11-19 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2018-11-16 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2018-09-04 | Eingeleitet | Citigroup | Buy |
| 2018-08-06 | Herabstufung | Goldman | Buy → Neutral |
| 2018-06-28 | Eingeleitet | Raymond James | Mkt Perform |
Alle ansehen
Madrigal Pharmaceuticals Inc Aktie (MDGL) Neueste Nachrichten
Madrigal Pharmaceuticals CEO sells shares worth $531,020 - MSN
(01/29/25) Top Picks 2025: Madrigal Pharmaceuticals (MDGL) - Moneyshow.com
Madrigal Pharmaceuticals chief commercial officer sells $116,328 in stock - MSN
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Insider Carole Huntsman Sells 347 Shares - MarketBeat
Insider Selling: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) CEO Sells 1,584 Shares of Stock - MarketBeat
Insider Selling: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) CMO Sells 648 Shares of Stock - MarketBeat
Insider Selling: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) VP Sells 103 Shares of Stock - MarketBeat
Madrigal Pharmaceuticals executive sells shares worth $34,529 - MSN
Madrigal Pharmaceuticals chief commercial officer sells $116,328 in stock By Investing.com - Investing.com South Africa
Madrigal Pharmaceuticals CEO sells shares worth $531,020 By Investing.com - Investing.com Australia
Madrigal Pharmaceuticals executive sells shares worth $34,529 By Investing.com - Investing.com Canada
(MDGL) Trading Advice - Stock Traders Daily
Madrigal Pharmaceuticals (MDGL) Stock Price, News & Analysis - MarketBeat
Exploring Three High Growth Tech Stocks in the United States - Yahoo Finance
Brokers Issue Forecasts for MDGL FY2025 Earnings - MarketBeat
Cantor Fitzgerald Estimates MDGL FY2025 Earnings - Defense World
MDGL (Madrigal Pharmaceuticals) Long-Term Debt & Capital Le - GuruFocus.com
Cantor Fitzgerald Predicts MDGL FY2025 Earnings - MarketBeat
MDGL (Madrigal Pharmaceuticals) Dividends per Share : $0.00 (TTM As of Sep. 2024) - GuruFocus.com
Madrigal Pharmaceuticals’ Treatment Could Be a Blockbuster in the Making - TipRanks
MDGL Stock Down 10% on Disappointing Preliminary Q4 Rezdiffra Sales - MSN
MDGL (Madrigal Pharmaceuticals) Change In Working Capital : $7.82 Mil (TTM As of Sep. 2024) - GuruFocus.com
Madrigal Pharmaceuticals exec sells $461,789 in stock - MSN
Madrigal Pharmaceuticals gains amid takeover speculation - MSN
MDGL (Madrigal Pharmaceuticals) Quick Ratio : 5.93 (As of Sep. 2024) - GuruFocus.com
Madrigal Pharmaceuticals Rezdiffra Vies For Blockbuster Status In MASH - Seeking Alpha
Have Insiders Sold Madrigal Pharmaceuticals Shares Recently? - Simply Wall St
MDGL (Madrigal Pharmaceuticals) Net Income From Continuing Operations : $-518.67 Mil (TTM As of Sep. 2024) - GuruFocus.com
MDGL (Madrigal Pharmaceuticals) EV-to-EBITDA : -10.99 (As of Jan. 19, 2025) - GuruFocus.com
MDGL (Madrigal Pharmaceuticals) Capex-to-Operating-Cash-Flo - GuruFocus.com
MDGL (Madrigal Pharmaceuticals) Earnings Yield % : N/A% (As of Jan. 19, 2025) - GuruFocus.com
MDGL (Madrigal Pharmaceuticals) 3-Year Book Growth Rate : 9.60% (As of Sep. 2024) - GuruFocus.com
MDGL (Madrigal Pharmaceuticals) Cash Flow for Lease Financing : $0.00 Mil (TTM As of Sep. 2024) - GuruFocus.com
MDGL (Madrigal Pharmaceuticals) Debt-to-Asset : 0.11 (As of Sep. 2024) - GuruFocus.com
Madrigal Pharmaceuticals executive sells shares worth $120,847 - MSN
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) VP Robert E. Waltermire Sells 442 Shares - MarketBeat
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) CMO Sells $461,789.49 in Stock - MarketBeat
Madrigal Pharmaceuticals exec sells $461,789 in stock By Investing.com - Investing.com South Africa
Madrigal Pharmaceuticals general counsel sells $75,734 in stock By Investing.com - Investing.com Australia
Madrigal Pharmaceuticals general counsel sells $75,734 in stock - Investing.com India
Madrigal Pharmaceuticals (NASDAQ:MDGL) Trading Up 7.4%Should You Buy? - MarketBeat
Shannon T. Kelley Sells 277 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Stock - MarketBeat
Madrigal Pharmaceuticals executive sells shares worth $120,847 By Investing.com - Investing.com Canada
Madrigral Pharmaceuticals gains amid takeover speculation - MSN
Why Madrigal Pharmaceuticals Stock Was Plummeting This Week - MSN
Madrigal Reports Robust 2024 Performance and Plans for Growth - MSN
Why Madrigal Pharmaceuticals (MDGL) Stock is Moving Today - GuruFocus.com
Finanzdaten der Madrigal Pharmaceuticals Inc-Aktie (MDGL)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.95%
2.39%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):